| OBJECTIVE: The aim of this study was to investigate the relationshipbetween the expression of ERCC1and chemosensitivity of oxaliplatin-based chemotherapy in advanced gastric cancer.METHODS: The immunohistochemistry(SP method) was used to examined theexpression of ERCC1of primary tumors in60cases of advanced gastriccancer. Patients were treated with oxaliplatin100mg/m2as a2hinfusion at day1plus Calcium Folinate400mg/m2,followed by5-Fu400mg/m2and46h continuous infusion of2400mg/m2at days1-2.Treatmentwas repeated in2-week intervals.After three periodic,response rateand time to progression(TTP) of all patients were used for analysisingthe association between ERCC1expression and chemosensitivity.RESULTS: The positive expression of ERCC1was detected in19of60advanced gastric cancer samples(31.67%).The patients without ERCC1expression were more likely to respond to chemotherapy(P=0.013).Thepatients with ERCC1negative expression showed a median TTP of8months,was not significantly different from5months in patients withthe positive ones(P=0.052).CONCLUSION: The results suggested that the expression of ERCC1wasassociated with the curative effect of oxaliplatin-based chemotherapyin patients with advanced gastric cancer.Patients with ERCC1positiveexpression showed no superiority from oxaliplatin-based chemotherapy,but need further demonstration. |
